Lv1
30 积分 2023-02-19 加入
Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization Versus Atezolizumab Plus Bevacizumab as First‐Line Therapy for Intermediate‐Stage Hepatocellular Carcinoma Beyond the Up‐to‐Seven Criteria
1天前
待确认
Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma
2天前
已完结
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study
3天前
已关闭
Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization
1个月前
已完结
Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma
2个月前
已完结
Confounding mitigation for the exposure‐response relationship of bevacizumab in colorectal cancer patients
2个月前
已完结
Bevacizumab exerts dose-dependent risk for intracranial hemorrhage in patients with malignant gliomas
2个月前
已完结
Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma
2个月前
已完结
Transcatheter Arterial Chemoembolization Plus Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma: a Single-Arm, Phase II Trial
3个月前
已完结
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
3个月前
已完结
皖公网安备34019202002308
